From Financial Modeling Prep: 2025-05-21 18:00:00

ICU Medical, Inc. (NASDAQ: ICUI) is facing an investigation by Pomerantz LLP for potential securities fraud after the FDA issued a warning about unauthorized changes to its infusion pump products. This led to a stock price drop of $6.04 per share, raising concerns about financial and reputational damage. Financial metrics indicate challenges, including a negative P/E ratio of -701.68 and a high price-to-sales ratio of 31.96.



Read more at Financial Modeling Prep:: ICU Medical, Inc. (NASDAQ: ICUI) Faces Investigation and Stock Impact